The Year in Interventional Cardiology

Journal of the American College of Cardiology

Volumn 47, Issue 8, 2006, Pages 1689-1706

  Dixon, Simon R ^a   Grines, Cindy L ^a   O'Neill, William W ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ABT 578; ACETYLSALICYLIC ACID; ADENOSINE; CILOSTAZOL; CLOPIDOGREL; ENOXAPARIN; EVEROLIMUS; FONDAPARINUX; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 34; NICORANDIL; PACLITAXEL; PIOGLITAZONE; PLASMID DNA; PRASUGREL; RAPAMYCIN; RETEPLASE; TENECTEPLASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOPLASTY; AORTA DISEASE; ARTERY INTIMA PROLIFERATION; BALLOON OCCLUSION; BIOCOMPATIBILITY; BLEEDING; BLOOD CLOT LYSIS; BRACHYTHERAPY; CARDIOGENIC SHOCK; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION; STEM CELL TRANSPLANTATION; STROKE; THROMBECTOMY; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME;

CARDIOLOGY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS;

EID: 33646075453     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.02.021     Document Type: Review

References (132)

1. Sutton A.G.C., Campbell P.G., Graham R., et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction (MERLIN). J Am Coll Cardiol 44 (2004) 287-296
2. Gershlick A.H., Stephens-Lloyd A., Hughes S., et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 353 (2005) 2758-2768
3. Le May M.R., Wells G.A., Labinaz M., et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 46 (2005) 417-424
4. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. JAMA 294 (2005) 1224-1232
5. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI). randomized trial. Lancet 367 (2006) 569-578
6. Mehta R.H., Granger C.B., Alexander K.P., et al. Reperfusion strategies for acute myocardial infarction in the elderly. J Am Coll Cardiol 45 (2005) 471-478
7. Grines C.L. A prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction (SENIOR-PAMI) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
8. Schomig A., Mehilli J., Antoniucci D., et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset. JAMA 293 (2005) 2865-2872
9. Mehta R.H., Harjai K.J., Cox D.A., et al. Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 96 (2005) 901-906
10. Herrmann H.C. Transfer for primary angioplasty. The importance of time. Circulation 111 (2005) 718-720
11. Nallamothu B.K., Bates E.R., Herrin J., et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States. Circulation 111 (2005) 761-767
12. De Luca G., Ernst N., Suryapranata H., et al. Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary angioplasty. Am J Cardiol 95 (2005) 1361-1363
13. Magid D.J., Wang Y., Herrin J., et al. Relationship between time of day, day of week, timeliness of reperfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction. JAMA 294 (2005) 803-812
14. Bradley E.H., Roumanis S.A., Radford M.J., et al. Achieving door-to-balloon times that meet quality guidelines. J Am Coll Cardiol 46 (2005) 1236-1241
15. Ross A.M., Gibbons R.J., Stone G.W., et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 45 (2005) 1775-1780
16. The CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. JAMA 293 (2005) 437-446
17. Timmer J. Glucose-insulin-potassium study in patients with ST elevation myocardial infarction without signs of heart failure (GIPS II) (2005) Presented at the Annual Scientific Session of the American College of Cardiology, Orlando, FL, March
18. Ishii H., Ichimiya S., Kanashiro M., et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment elevation myocardial infarction. Circulation 112 (2005) 1284-1288
19. Burzotta F., Trani C., Romagnoli E., et al. Manual thrombus-aspiration improves myocardial reperfusion. J Am Coll Cardiol 46 (2005) 371-376
20. Lefevre T., Garcia E., Reimers B., et al. X-Sizer thrombectomy in acute myocardial infarction improves ST-segment resolution. J Am Coll Cardiol 46 (2005) 246-252
21. Kaltoft A. A prospective randomized trial of thrombus aspiration in patients with acute myocardial infarction undergoing primary angioplasty (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
22. Stone G.W., Webb J., Cox D.A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. JAMA 293 (2005) 1063-1072
23. Gick M., Jander N., Bestehorn H.P., et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 112 (2005) 1462-1469
24. Schachinger V., Erbs S., Elsasser A., et al. Intracoronary infusion of bone marrow-derived progenitor cells in acute myocardial infarction. a randomized, double-blind, placebo-controlled multicenter trial (REPAIR-AMI). Circulation 112 (2005) 3362
25. Lunde K., Solheim S., Aakhus S., et al. Effects on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction. the ASTAMI randomized controlled trial. Circulation 112 (2005) 3362
26. Bartunek J., Vanderheyden M., Vanderkerckhove B., et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction. Circulation 112 Suppl I (2005) I178-I183
27. Ince H., Petzsch M., Kleine H.D., et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction. Final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony Stimulating Factor (FIRSTLINE-AMI) trial. Circulation 112 Suppl I (2005) I73-I80
28. Ince H., Petzsch M., Kleine H.D., et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 112 (2005) 3097-3106
29. Zohlnhofer D. A prospective randomized, double-blind trial of granulocyte colony stimulating factor in patients with acute myocardial infarction (REVIVAL-2) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
30. Zbinden S., Zbinden R., and Meier P. Safety and efficacy of subcutaneous only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 46 (2005) 1636-1642
31. Hill J.M., Syed M.A., and Arai A.E. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46 (2005) 1643-1648
32. Klein L.W., Shaw R.E., Krone R.J., et al. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol 96 (2005) 35-41
33. Babaev A., Frederick P.D., Pasta D.J., et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 294 (2005) 448-454
34. White H.D., Assmann S.F., Sanborn T.A., et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock. Circulation 112 (2005) 1992-2001
35. Dzavik V., Sleeper L.A., Picard M.H., et al. Outcome of patients aged ≥75 years in the Should we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial. do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization. Am Heart J 149 (2005) 1128-1134
36. Kim J., Henderson R.A., Pocock S.J., et al. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 45 (2005) 221-228
37. Fox K.A.A., Poole-Wilson P., Clayton T.C., et al. 5-year outcome of an interventional strategy in non-ST elevation acute coronary syndrome. the British Heart Foundation RITA-3 randomised trial. Lancet 366 (2005) 914-920
38. Mehta S.R., Cannon C.P., Fox K.A.A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes. A collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
39. Biondi-Zoccai G.G., Abbate A., Agostoni P., et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment. a metaregression. Am Heart J 149 (2005) 504-511
40. de Winter R.J., Windhausen F., Cornel J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353 (2005) 1095-1104
41. Serruys P.W., Ong A.T.L., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease. J Am Coll Cardiol 46 (2005) 575-581
42. Rodriguez A.E., Baldi J., Pereira C.F., et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multivessel disease (ERACI II). J Am Coll Cardiol 46 (2005) 582-588
43. Hannan E.L., Racz M.J., Walford G., et al. Long-term outcomes of coronary artery bypass grafting versus stent implantation. N Engl J Med 352 (2005) 2174-2183
44. Malenka D.J., Leavitt B.J., Hearne M.J., et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI. Analysis of BARI-like patients in Northern New England. Circulation 112 Suppl I (2005) I371-I376
45. McLellan C.S., Ghali W.A., Labinaz M., et al., Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 150 (2005) 800-806
46. Stone G.W., Kandzari D.E., Mehran R., et al. Percutaneous recanalization of chronically occluded coronary arteries. A consensus document part I. Circulation 112 (2005) 2364-2372
47. Stone G.W., Reifart N.J., Moussa I., et al. Percutaneous recanalization of chronically occluded coronary arteries. A consensus document part II. Circulation 112 (2005) 2530-2537
48. Abbas A.E., Brewington S.D., Dixon S.R., et al. Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion. J Am Coll Cardiol 46 (2005) 793-798
49. Leon M.B., Kornowski R., Downey W.E., et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 46 (2005) 1812-1819
50. Hannan E.L., Wu C., Walford G., et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation 112 (2005) 1171-1179
51. Moscucci M., Share D., Smith D., et al. Relationship between operator volume and adverse outcome in contemporary percutaneous coronary intervention practice. An analysis of a quality-controlled multicenter percutaneous coronary intervention clinical database. J Am Coll Cardiol 46 (2005) 625-632
52. Cram P., Rosenthal G.E., and Vaughan-Sarrazin M.S. Cardiac revascularization in specialty and general hospitals. N Engl J Med 352 (2005) 1454-1462
53. Moscucci M., Eagle K.A., Share D., et al. Public reporting and case selection for percutaneous coronary interventions. J Am Coll Cardiol 45 (2005) 1759-1765
54. Ix J.H., Mercado N., Shlipak M.G., et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization. the Arterial Revascularization Therapies Study (ARTS). Am Heart J 149 (2005) 512-519
55. Lemos P.A., Arampatzis C.A., Hoye A., et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 95 (2005) 167-172
56. Dangas G., Iakovou I., Nikolsky E., et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95 (2005) 13-19
57. 165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 45 (2005) 982-988
58. Strauer B.E., Brehm M., Zeus T., et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease. J Am Coll Cardiol 46 (2005) 1651-1658
59. Aoki J., Serruys P.W., van Beusekom H., et al. Endothelial progenitor cell capture by stents coated with antibody against CD34. The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 45 (2005) 1574-1579
60. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery. PREVENT IV: a randomized controlled trial. JAMA 294 (2005) 2446-2454
61. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease. Meta-analysis of randomized trials. JAMA 294 (2005) 819-825
62. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. A randomized controlled trial. JAMA 293 (2005) 165-171
63. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
64. Goy J.J., Stauffer J.C., Siegenthaler M., et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. The TAXi trial. J Am Coll Cardiol 45 (2005) 308-311
65. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
66. Morice M.C. Eight-month outcome of the REALITY trial. A prospective, randomized multicenter head-to-head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus) (2005) Presented at the Annual Scientific Session of the American College of Cardiology, Orlando, FL, March
67. de Lezo J., Medina A., Pan M., et al. Drug-eluting stents for complex lesions. randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol 45 Suppl (2005) 75A
68. Sousa J.E., Costa M.A., Abizaid A., et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 111 (2005) 2326-2329
69. Fajadet J., Morice M.C., Bode C., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. Three-year results of the RAVEL trial. Circulation 111 (2005) 1040-1044
70. Wijns W. A randomized comparison of the Endeavor ABT-578 drug eluting stent with a bare metal stent for coronary revascularization. results of the ENDEAVOR II trial (2005) Presented at the Annual Scientific Session of the American College of Cardiology, Orlando, FL, March
71. Kandzari D. A prospective, randomized comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with coronary artery disease (ENDEAVOR-III) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
72. Kastrati A. A prospective, randomized trial of the Yukon non-polymer-based rapamycin-coated stent and the polymer-based paclitaxel-eluting stent in patients with coronary artery disease (ISAR-TEST) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
73. Morice M.C. A prospective randomized trial of a tacrolimus-eluting stent compared to a carbon-coated stent in patients with coronary artery disease (JUPITER-II) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
74. Costa R.A., Lansky A.J., Mintz G.S., et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 95 (2005) 113-116
75. Mauri L., Orav E.J., and Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 111 (2005) 3435-3442
76. Hwang C.W., Levin A.D., Jonas M., et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111 (2005) 1619-1626
77. Bavry A.A., Kumbhani D.J., Helton T.J., and Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 45 (2005) 941-946
78. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
79. Fujii K., Carlier S.G., Mintz G.S., et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. J Am Coll Cardiol 45 (2005) 995-998
80. Tanabe K., Serruys P.W., Degertekin M., et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents. Circulation 111 (2005) 900-905
81. Ako J., Morino Y., Honda Y., et al. Late incomplete stent apposition after sirolimus-eluting stent implantation. A serial intravascular ultrasound analysis. J Am Coll Cardiol 46 (2005) 1002-1005
82. Ong A.T.L., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
83. Ong A.T.L., Hoye A., Aoki J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
84. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting compared with a third generation bare-metal stent in a real-world setting. randomized Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
85. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. A randomized controlled trial. JAMA 294 (2005) 1215-1223
86. Dawkins K.D., Grube E., Guagliumi G., et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial. support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112 (2005) 3306-3313
87. Kelbaek H. Randomized multicenter comparison of sirolimus versus bare metal stent implantation in complex coronary disease. The Stenting of Coronary Arteries in Non-Stress/Benestent Disease trial (SCANDSTENT) (2005) Presented at the Annual Scientific Session of the American College of Cardiology, Orlando, FL, March
88. Sabaté M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients. The Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
89. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
90. Singh M., Gersh B.J., McClelland R.L., et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 45 (2005) 198-203
91. Dangas G., Ellis S.G., Shlofmitz R., et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 45 (2005) 1186-1192
92. Seung K.B., Kim Y.K., Park D.W., et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 46 (2005) 787-792
93. Tsagalou E., Chieffo A., Iakovou I., et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 45 (2005) 1570-1573
94. Park S.J., Kim Y.H., Lee B.K., et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. Comparison with bare metal stent implantation. J Am Coll Cardiol 45 (2005) 351-356
95. Valgimigli M., van Mieghem C.A.G., Ong A.T.L., et al. Short- and long-term clinical outcomes after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease. Circulation 111 (2005) 1383-1389
96. Chieffo A., Stankovic G., Bonizzoni E., et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 111 (2005) 791-795
97. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction. A randomized trial. JAMA 293 (2005) 2109-2117
98. Ge L., Iakovou I., Sangiorgi G.M., et al. Treatment of saphenous vein graft lesions with drug-eluting stents. Immediate and midterm outcomes. J Am Coll Cardiol 45 (2005) 989-994
99. Moses J.W., Mehran R., Nikolsky E., et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes. Analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1165-1171
100. Neumann F.J., Desmet W., Grube E., et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 111 (2005) 2107-2111
101. Nakamura S., Muthusamy T.S., Bae J.H., et al. Impact of sirolimus-eluting stent in the outcome of patients with chronic total occlusions. Am J Cardiol 95 (2005) 161-166
102. Suttorp M.J. A prospective randomized trial of sirolimus-eluting and bare metal stents in patients with chronic total occlusions (PRISON II) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
103. Holmes D.R. A prospective randomized comparison of the sirolimus-eluting stent vs brachytherapy in patients with bare metal in-stent restenosis (SISR) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
104. Windecker S., Simon R., Lins M., et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization. The TiNOX trial. Circulation 111 (2005) 2617-2622
105. Douglas J.S., Holmes D.R., Kereiakes D.J., et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 (2005) 2826-2832
106. Marx N., Wöhrle J., Nusser T., et al. Pioglitazone reduces neointimal volume after coronary stent implantation. A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 (2005) 2792-2798
107. Zohlnhofer D., Hausleiter J., Kastrati A., et al. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor Imatinib. J Am Coll Cardiol 46 (2005) 1999-2003
108. Dixon S.R. Saphenous vein graft protection in a distal embolic protection randomized trial (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
109. Carrozza J.P., Mumma M., Breall J., et al. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol 46 (2005) 1677-1683
110. Rogers C. Proximal protection during saphenous vein graft intervention using the Proxis embolic protection system. a randomized, prospective, multicenter clinical trial (PROXIMAL) (2005) Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, October
111. Quan V.H., Huynh R., Seifert P.A., et al. Morphometric analysis of particulate debris extracted by four different embolic protection devices from coronary arteries, aortocoronary saphenous vein conduits, and carotid arteries. Am J Cardiol 95 (2005) 1415-1419
112. Giugliano G.R., Kuntz R.E., Popma J.J., et al. Determinants of 30-day adverse cardiac events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 95 (2005) 173-177
113. Blakensteijn J.D., de Jong S.E.C.A., Prinssen M., et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 352 (2005) 2398-2405
114. EVAR Trial Participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1). randomised controlled trial. Lancet 365 (2005) 2179-2186
115. EVAR Trial Participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2). randomised controlled trial. Lancet 365 (2005) 2187-2192
116. Rosenfield K., Cowley M.J., Jaff M.R., et al. SCAI/SVMB/SVS clinical competence statement on carotid stenting. training and credentialing for carotid stenting - multispecialty consensus recommendations, a report of the SCAI/SVMB/SVS writing committee to develop a clinical competence statement on carotid interventions. J Am Coll Cardiol 45 (2005) 165-174
117. Casserly I.P., Abou-Chebl A., Fathi R.B., et al. Slow-flow phenomenon during carotid artery intervention with embolic protection devices. Predictors and clinical outcome. J Am Coll Cardiol 46 (2005) 1466-1472
118. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. A meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
119. Bertrand O.F. Same-day home discharge after transradial coronary stenting with a single abciximab bolus. 6-month results of the EASY randomized trial. Circulation 112 (2005) 3362
120. Silberman S., Neukirch-Stoop C., and Steg P.G. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 95 (2005) 509-510
121. Serbruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 patients. J Am Coll Cardiol 45 (2005) 246-251
122. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
123. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting. Results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46 (2005) 1820-1826
124. Gurbel P.A., Bliden K.P., Hayes K.M., et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
125. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE trial. Circulation 112 (2005) 2946-2950
126. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
127. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty study). Circulation 111 (2005) 2099-2106
128. Gurbel P.A., Bliden K.P., Zaman K.A., et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets. Results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
129. Lee S.W., Park S.W., Hong M.K., et al. Triple versus dual antiplatelet therapy after coronary stenting. Impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
130. 12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medication to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
131. Mahaffey K.W., Cohen M., Garg J., et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin. Outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 294 (2005) 2594-2600
132. Mehta S.R., Steg P.G., Granger C.B., et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention. Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial. Circulation 111 (2005) 1390-1397